Leadership & Pay ·
Ovid Therapeutics Inc. announced an executive transition where Jeffrey Rona, the Chief Business and Financial Officer…
OVIDOvid Therapeutics Inc.
Ovid Therapeutics Inc. announced an executive transition where Jeffrey Rona, the Chief Business and Financial Officer, principal financial officer, principal accounting officer, and secretary, will transition from his roles effective July 6, 2026. Charles Carter, previously the Company's Senior Vice President of Finance and Financial Planning, has been appointed as the new Chief Financial Officer, principal financial officer, principal accounting officer, and secretary, effective July 6, 2026. Mr. Carter's compensation package includes a $460,000 annual base salary, a 35% target cash bonus, and a 50,000 share restricted stock unit award. Ovid Therapeutics Inc. is a biotechnology company focused on developing and commercializing therapeutic solutions for neurological and psychiatric disorders.